Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $2.5 million.

  • Voyager Therapeutics' Treasury Shares rose 5667.62% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 5667.62%. This contributed to the annual value of $1.6 million for FY2024, which is 2035.5% up from last year.
  • Latest data reveals that Voyager Therapeutics reported Treasury Shares of $2.5 million as of Q3 2025, which was up 5667.62% from $2.7 million recorded in Q2 2025.
  • Voyager Therapeutics' Treasury Shares' 5-year high stood at $2.8 million during Q1 2025, with a 5-year trough of $806379.0 in Q4 2021.
  • Over the past 5 years, Voyager Therapeutics' median Treasury Shares value was $1.3 million (recorded in 2023), while the average stood at $1.5 million.
  • As far as peak fluctuations go, Voyager Therapeutics' Treasury Shares soared by 11504.86% in 2021, and later crashed by 3169.91% in 2022.
  • Quarter analysis of 5 years shows Voyager Therapeutics' Treasury Shares stood at $806379.0 in 2021, then skyrocketed by 37.97% to $1.1 million in 2022, then rose by 23.22% to $1.4 million in 2023, then rose by 20.35% to $1.6 million in 2024, then soared by 53.55% to $2.5 million in 2025.
  • Its Treasury Shares stands at $2.5 million for Q3 2025, versus $2.7 million for Q2 2025 and $2.8 million for Q1 2025.